Abingworth LL.P. is an investment fund managing more than $312 million ran by John Heard. There are currently 21 companies in Mr. Heard’s portfolio. The largest investments include Vaxcyte and Sierra Oncology Inc, together worth $163 million.
As of 8th August 2022, Abingworth LL.P.’s top holding is 4,168,718 shares of Vaxcyte currently worth over $90.7 million and making up 29.0% of the portfolio value.
Relative to the number of outstanding shares of Vaxcyte, Abingworth LL.P. owns less than approximately 0.1% of the company.
In addition, the fund holds 1,314,127 shares of Sierra Oncology Inc worth $72.3 million, whose value grew 69.2% in the past six months.
The third-largest holding is Vera worth $40.3 million and the next is Adicet worth $30.9 million, with 2,115,385 shares owned.
Currently, Abingworth LL.P.'s portfolio is worth at least $312 million. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Abingworth LL.P. office and employees reside in London, United Kingdom. According to the last 13-F report filed with the SEC, John Heard serves as the General Counsel at Abingworth LL.P..
In the most recent 13F filing, Abingworth LL.P. revealed that it had opened a new position in
Hillevax and bought 1,838,486 shares worth $19.9 million.
The investment fund also strengthened its position in Sierra Oncology Inc by buying
115 additional shares.
This makes their stake in Sierra Oncology Inc total 1,314,127 shares worth $72.3 million.
Sierra Oncology Inc dropped approximately 0.1% in the past year.
On the other hand, John Heard disclosed a decreased stake in Sientra Inc by 0.3%.
This leaves the value of the investment at $1.39 million and 1,673,589 shares.
The two most similar investment funds to Abingworth LL.P. are Genwealth and Alpinvest Partners B.v. They manage $312 million and $312 million respectively.
Abingworth LL.P.’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 52.9% of
the total portfolio value.
The fund focuses on investments in the United States as
28.6% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
14% of the total holdings value.
On the other hand, large-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $488 million.
These positions were updated on August 15th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Vaxcyte, Inc. |
No change
4,168,718
|
$90,711,000 | 29.04% |
| Sierra Oncology Inc |
0.01%
1,314,127
|
$72,277,000 | 23.14% |
| Vera |
No change
2,960,231
|
$40,289,000 | 12.90% |
| Adicet |
No change
2,115,385
|
$30,885,000 | 9.89% |
| Hillevax |
Opened
1,838,486
|
$19,929,000 | 6.38% |
| Phathom |
No change
1,435,106
|
$12,112,000 | 3.88% |
| Jasper |
No change
5,628,558
|
$10,638,000 | 3.41% |
| Verona |
0.00%
2,457,500
|
$10,174,000 | 3.26% |
| Effector |
No change
4,822,114
|
$6,462,000 | 2.07% |
| Reneo |
No change
2,073,957
|
$5,413,000 | 1.73% |
| Soleno |
No change
18,022,602
|
$3,165,000 | 1.01% |
| Spruce Bio |
No change
1,792,518
|
$3,101,000 | 0.99% |
| Nucana |
No change
3,333,333
|
$2,417,000 | 0.77% |
| Paratek |
No change
1,041,131
|
$1,999,000 | 0.64% |
| Sientra Inc |
28.78%
1,673,589
|
$1,389,000 | 0.44% |
| Exicure Inc |
95.96%
281,636
|
$594,000 | 0.19% |
| Cymabay |
No change
131,036
|
$385,000 | 0.12% |
| Molecular Templates Inc |
No change
200,000
|
$182,000 | 0.06% |
| Obseva |
No change
87,999
|
$141,000 | 0.05% |
| Aeglea |
No change
240,500
|
$121,000 | 0.04% |
| Ocugen Inc |
No change
7,111
|
$16,000 | 0.01% |
| No transactions found | |||
| Showing first 500 out of 21 holdings | |||